• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 23, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Scientists show we don’t need horses to treat diphtheria

Bioengineer by Bioengineer
January 21, 2020
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Research funded by PETA Science Group breaks new ground with animal-free antibodies

IMAGE

Credit: PETA India

London – A project taking the first steps towards ending the use of horses to treat diphtheria has succeeded.

Funded by the PETA International Science Consortium Ltd. and carried out at the Institute of Biochemistry, Biotechnology, and Bioinformatics at the Technische Universität Braunschweig in Germany, the project created human antibodies capable of blocking the poisonous toxin that causes diphtheria. The results were published Friday in Scientific Reports (a Nature research journal).

Diphtheria is a potentially deadly infectious disease causing severe respiratory distress and damage to vital organs and is a significant human health burden. For more than 100 years, the main method of producing the antitoxin to treat it has been to inject horses repeatedly with the diphtheria toxin and then drain them of huge amounts of their blood in order to collect the antibodies that their immune systems produce to fight the disease. This animal-derived antitoxin has the potential to cause serious allergic reactions in humans, and global health authorities report having difficulty acquiring sufficient stockpiles of these antitoxins to respond quickly to diphtheria outbreaks.

Inspections of facilities where horses are used to produce animal-derived antitoxins have found widespread neglect of animal welfare regulations, with horses confined to filthy, severely crowded enclosures and suffering from anaemia, diseased hooves, eye abnormalities, infections, parasites, and malnutrition.

Rather than using horses, the researchers involved in this project used human blood cells to create human antibodies that block the diphtheria toxin. The Science Consortium is now working with its research partners to ensure that the non-animal antitoxin is developed into a medicine that will be used to treat this menacing disease more reliably and safely without causing a single horse to suffer.

“Thousands of horses worldwide are forced to endure cruel treatment for the production of many different types of drugs, not just diphtheria antitoxin,” says Jeffrey Brown, adviser to the PETA International Science Consortium and co-author of the paper. “Solid science has now given these horses a way out of this suffering.”

###

The PETA International Science Consortium Ltd. works to accelerate the development, validation, and global implementation of animal-free testing. It was established in 2012 to coordinate the scientific and regulatory expertise of its members – PETA US, PETA UK, PETA Germany, PETA India, PETA Netherlands, PETA France, PETA Asia, and PETA Australia. The Science Consortium and its members have donated millions of pounds towards helping to reduce and replace animal use.

For more information, please visit PISCLtd.org.uk.

Media Contact
Tasgola Bruner
[email protected]
404-907-4172

Related Journal Article

http://dx.doi.org/10.1038/s41598-019-57103-5

Tags: Cell BiologyDisease in the Developing WorldHealth CareInfectious/Emerging DiseasesMedicine/HealthPharmaceutical SciencePublic HealthVaccines
Share12Tweet8Share2ShareShareShare2

Related Posts

Inside CNS Solitary Fibrous Tumors: Genetics and Therapies

Inside CNS Solitary Fibrous Tumors: Genetics and Therapies

August 23, 2025
Brain-Delivered Antibody Targets Alpha-Synuclein Aggregates

Brain-Delivered Antibody Targets Alpha-Synuclein Aggregates

August 23, 2025

Multi-Omics Reveal Nerve Macrophages in Polyneuropathy

August 23, 2025

Optimizing Basal Insulin Titration: Digital Solutions in India

August 23, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    114 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Impact of Moderate Warming on Soil Microbial Decomposition

Inside CNS Solitary Fibrous Tumors: Genetics and Therapies

Brain-Delivered Antibody Targets Alpha-Synuclein Aggregates

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.